Daiichi Sankyo Files For Additional Indication Of Methylene Blue For Methemoglobinemia
This article was originally published in PharmAsia News
Executive Summary
Daiichi Sankyo filed an application for the approval of Methylene Blue (methylthioninium chloride) for the treatment of methemoglobinemia, the company announced on March 17.